readthroughSign in
Nov 16, 2026Trial update

BMS registers Phase 1/2a trial of BMS-986548 in KRAS-altered solid tumors

Bristol-Myers Squibb listed a new early-phase study testing BMS-986548 alone and with cetuximab in NSCLC, colorectal, and pancreatic cancers.

Bristol-Myers Squibb registered one new trial this week.

  • A Phase 1/2a, open-label study (NCT07939815) will test BMS-986548 as a single agent and combined with cetuximab in people with advanced solid tumors carrying a KRAS alteration. The study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of BMS-986548 given alone and alongside other anti-cancer agents.1 It is listed as not yet recruiting, with an estimated enrollment of 171 participants1 and an estimated enrollment of 171 participants.1 The record covers non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.1 Estimated start is 2026-11-30, with primary completion estimated for 2029-12-29.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.